The prevalence of potentially pathogenic germline BARD1 variants has been investigated in colorectal [32,69], endometrial [70] and pancreatic [71,72] cancers (Figure 2A,B, Supplementary Table S1). The gene discussed is BARD1; the disease is cancer.